Get the Stockscreener App
12.48
0.09%
0.035
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $12.48, with a volume of 3.37M.
It is up +0.09% in the last 24 hours and up +16.35% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$12.45
Open:
$12.5
24h Volume:
3.37M
Relative Volume:
0.41
Market Cap:
$14.37B
Revenue:
$14.33B
Net Income/Loss:
$-3.79B
P/E Ratio:
-3.9385
EPS:
-3.17
Net Cash Flow:
$1.84B
1W Performance:
+1.14%
1M Performance:
+16.35%
6M Performance:
+33.42%
1Y Performance:
+0.33%
1-Day Range:
$12.27
$12.54
1-Week Range:
$12.25
$12.62
52-Week Range:
$6.85
$12.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
12.47 | 14.34B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
125.06 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.59 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
9.99 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.73 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
492.00 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Overweight |
| Oct-15-25 | Initiated | Truist | Buy |
| Jun-06-25 | Initiated | Goldman | Neutral |
| Jul-19-24 | Resumed | Jefferies | Buy |
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Insider Monkey
Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $12.60 - Investing.com India
Viatris Inc. stock rises Wednesday, outperforms market - MSN
Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves - Insider Monkey
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Earnings Notes - Trefis
Viatris Inc. Stock Climbs 1.8%, Outperforms Market - 富途牛牛
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025 - FinancialContent
How Is The Market Feeling About Viatris Inc? - Benzinga
Is Viatris stock outperforming the Dow? - MSN
Viatris: Looks Cheap, But Faces Continued Contraction (NASDAQ:VTRS) - Seeking Alpha
Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn
Why Viatris Inc. stock remains on buy listsWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance
Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia
Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber
Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech
Viatris secures four regulatory milestones across global pipeline By Investing.com - Investing.com Australia
Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber
Viatris Provides Pipeline Update on Four Regulatory Milestones - The Malaysian Reserve
Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Viatris racks up regulatory wins across therapy areas - The Pharma Letter
Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com
Rally Mode: How Viatris Inc VIA stock behaves in tightening cyclesQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - moha.gov.vn
Viatris secures four regulatory milestones across global pipeline - Investing.com
Viatris provides pipeline update on four regulatory milestones - marketscreener.com
Viatris Provides Pipeline Update On Four Regulatory Milestones - TradingView — Track All Markets
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Malaysian Reserve
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Con - GuruFocus
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Does Viatris’ Reshaping Strategy Make Sense After Recent Share Price Swings? - Yahoo Finance
Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back - The Globe and Mail
Insomnia Drugs Market Outlook 2026-2034: Trends, Shares, and Growth Analysis Featuring Merck & Co., - PharmiWeb.com
Is Viatris Stock Outperforming the Dow? - Yahoo Finance
Lost Money on Viatris Inc. (VTRS)? Contact Levi & Korsinsky to Join Class Action Before June 3, 2025 - 28/22 News
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - 28/22 News
Non-operating income (total) of Viatris, Inc. – SIX:VTRS.USD - TradingView — Track All Markets
Risk Analysis: How Viatris Inc VIA stock behaves in tightening cyclesJuly 2025 Snapshot & Verified Swing Trading Watchlist - moha.gov.vn
Discipline and Rules-Based Execution in VTRS Response - news.stocktradersdaily.com
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
How Viatris Inc stock reacts to global recession fearsJuly 2025 Spike Watch & Consistent Return Investment Signals - moha.gov.vn
Viatris to Sell Entire Equity Stake in Biocon Biologics for $815 Million - Voice Of HealthCare
Barclays Initiates Coverage of Viatris (VTRS) with Overweight Recommendation - Nasdaq
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
2.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):